TNF and myeloid sarcoma: Withdrawal of an effective DMT [12], monoclonal antibodies targeting tumor necrosis factor alpha (TNF-α) [13], gonadotropin-releasing hormone antagonists (used in the treatment of infertility, hormone-sensitive breast and prostate cancers, certain gynecological disorders and as part of hormone therapy in transgender patients) can also increase the risk of MS relapse [14].